SGLT2 Inhibitors in Clinical Practice: Cardiorenal Benefits and Risk of Fungal Infections—A Nephrologist’s Perspective
Journal of Clinical Medicine · 29.04.2026 · 15 (9) · 3395
DOI: 10.3390/jcm15093395 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Clinical Medicine, online erschienen am 29.04.2026. Verfasst von Wiktoria Andryszkiewicz und 3 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine, Wroclaw Medical University, 50-367 Wroclaw, Poland. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
People affected by diabetes mellitus (DM), chronic kidney disease (CKD), or heart failure are often prescribed sodium–glucose cotransporter-2 inhibitors (SGLT2is) as a method of treatment. These drugs favorably affect glucose metabolism, as patients taking them have lower serum glucose levels. Another promising positive impact is protection against microvascular damage, cardiovascular disease, and chronic kidney disease. Nevertheless, fungal infections, urinary tract infections, and ketoacidosis are the adverse effects that might happen during the SGLT2i treatment. Fungal infections are more common among patients treated with these medications, including vulvovaginal Candidiasis in women and balanitis or balanoposthitis in men. Given the difficulty of treating fungal infections in patients with co-occurring diseases, we recommend that ongoing supervision of patients treated with SGLT2i include prevention and early detection of fungal infections.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Faculty of Medicine, Wroclaw Medical University, 50-367 Wroclaw, Poland.
- Department of Nephrology, Transplantation Medicine and Internal Diseases, Wroclaw Medical University, 50-367 Wroclaw, Poland.
ORCID-Profile: Wiktoria Andryszkiewicz, Maria Kręcicka, Sławomir Zmonarski
Zitieren
APA
Andryszkiewicz, W., Cichowska, Z., Kręcicka, M., & Zmonarski, S. (2026). SGLT2 Inhibitors in Clinical Practice: Cardiorenal Benefits and Risk of Fungal Infections—A Nephrologist’s Perspective. Journal of Clinical Medicine, 15(9), 3395. https://doi.org/10.3390/jcm15093395
Vancouver
Andryszkiewicz W, Cichowska Z, Kręcicka M, Zmonarski S. SGLT2 Inhibitors in Clinical Practice: Cardiorenal Benefits and Risk of Fungal Infections—A Nephrologist’s Perspective. Journal of Clinical Medicine. 2026;15(9):3395. doi:10.3390/jcm15093395
BibTeX
@article{Andryszkiewicz2026,
author = {Andryszkiewicz, Wiktoria and Cichowska, Zuzanna and Kręcicka, Maria and Zmonarski, Sławomir},
title = {SGLT2 Inhibitors in Clinical Practice: Cardiorenal Benefits and Risk of Fungal Infections—A Nephrologist’s Perspective},
journal = {Journal of Clinical Medicine},
year = {2026},
volume = {15},
number = {9},
pages = {3395},
doi = {10.3390/jcm15093395}
}
EUVIMED